DRUG | Overlaps between known targets and predicted targets | # of overlaps |
---|---|---|
Regorafenib | RET; FLT1; KDR; KIT; PDGFRA; PDGFRB; FGFR1; TEK; NTRK1; EPHA2; ABL1 | 11 |
Tamoxifen | ESR1; ESR2; PRKCA; PRKCB; PRKCD; PRKCE; PRKCG; PRKCQ; PRKCZ; ESRRG | 10 |
Ponatinib | ABL1; KIT; RET; TEK; FGFR1; LCK; SRC; LYN; KDR; PDGFRA | 10 |
Dasatinib | ABL1; SRC; FYN; LCK; KIT; PDGFRB; EPHA2; BTK; FGR; LYN | 10 |
Imatinib | PDGFRB; ABL1; KIT; RET; NTRK1; CSF1R; PDGFRA | 7 |
Brigatinib | EGFR; ABL1; IGF1R; INSR; MET; ERBB2 | 6 |
Sorafenib | PDGFRB; KIT; KDR; FGFR1; RET; FLT1 | 6 |
Sunitinib | PDGFRB; FLT1; KDR; KIT; CSF1R; PDGFRA | 6 |
Nintedanib | FLT1; KDR; FGFR1; LCK; LYN; SRC | 6 |
Pazopanib | FLT1; KDR; PDGFRA; PDGFRB; KIT | 5 |
Midostaurin | PRKCA; KDR; KIT; PDGFRA; PDGFRB | 5 |
Resveratrol | ITGA5; ITGB3; SNCA; ESR1; AKT1 | 5 |
Diethylstilbestrol | ESR1; ESRRG; ESR2; ESRRA | 4 |
Tofacitinib | TYK2; JAK2; JAK1; JAK3 | 4 |
Lenvatinib | FLT1; KDR; FGFR1; KIT | 4 |
Foreskin fibroblast (neonatal) | FLT1; CSF2RA; PDGFRB; TGFB1 | 4 |
Baricitinib | JAK1; JAK2; PTK2B; JAK3 | 4 |
Foreskin keratinocyte (neonatal) | EGFR; CSF2RA; PDGFRA; TGFB1 | 4 |
Bosutinib | ABL1; LYN; SRC | 3 |
Estradiol valerate | ESR1; ESR2; ESRRG | 3 |